Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer

Taruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir · 2024

Read Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer by Taruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11623886.txt.

Description

Taruba Rais and four colleagues review repotrectinib, a newly approved drug for advanced non-small cell lung cancer, in a 2024 paper. This cancer type causes most lung cancer deaths, and tumors driven by ROS1 or NTRK gene changes need targeted options. Repotrectinib blocks the faulty kinases behind those changes. In the TRIDENT-1 trial it delivered strong response rates and lasting benefit, including inside the brain, for both new and previously treated patients. Its side effects looked manageable, and the authors present it as a meaningful addition for these tumor types.

Catalog record

CREATORTaruba Rais, Amna Shakeel, Laiba Naseem, Nathalie Nasser, Minahil Aamir
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11623886

Browse the full library · About the Tower of Babel